AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01988324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy
Study NCT01988324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study NCT01418469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caseinate
Description: 18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
Study NCT01418469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: 18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
Study NCT01418469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: 18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
Study NCT01418469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy+BCAA
Description: 18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
Study NCT02785211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment
Description: The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
Study NCT02785211 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Activation Treatment
Description: The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
Study NCT04615936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylene-Blue Photodisinfection
Description: Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
Study NCT00614835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Gemcitabine
Description: Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
Study NCT00299858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
Study NCT00299858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
Study NCT03371914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Management training and data feedback
Description: The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
Study NCT01780623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright white light
Study NCT01780623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim red light
Study NCT02497469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab infusion
Study NCT02497469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab placebo
Description: Adalimumab placebo-matching injection
Study NCT02497469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab injection
Study NCT02497469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching infusion
Study NCT01969526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
Study NCT04942262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denture adhesive (Polident®, GlaxoSmithKline, Ireland)
Description: cream-type denture adhesive available as an over-the-counter product in Thailand
Study NCT02818504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wize Mirror
Description: Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
Study NCT00919880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin+ paclitaxel
Description: carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study NCT00919880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study NCT00919880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study NCT02075125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Description: Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
Study NCT02075125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Description: Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
Study NCT00686972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
Study NCT01901185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept / Autoinjector A
Description: Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
Study NCT02524119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
Study NCT02524119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
Study NCT03555799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inferior vena cava ultrasound
Description: Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
Study NCT03453294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation using THRIVE
Description: Apnoeic oxygenation using THRIVE
Study NCT03453294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation and mechanical ventilation
Description: Endotracheal intubation and mechanical ventilation
Study NCT02192788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy for Oligometastases
Study NCT04549194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: A blood sample will be collected before during and after the treatment.
Study NCT04549194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Tyrosine 500 Mg
Description: The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
Study NCT04549194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires
Description: The participants will fill in several psychological questionnaires before, during and after treatment administration:~* Life Event Checklist~* Moral injury~* Posttraumatic Checklist~* Burnout Assessment Tool~* State-Trait Anger Expression Inventory-2~* Ruminative Response Scale - Reconsidered~* Deployment Risk and Resilience Inventory-2~* Questionnaire about tobacco use
Study NCT04549194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Description: Photoplethysmography recording will be performed before during and after the treatment.
Study NCT04549194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
Study NCT00591877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus.
Study NCT00591877 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae.
Study NCT00591877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
Study NCT04376281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
Study NCT05068843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic partial meniscectomy
Description: In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
Study NCT05068843 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
Study NCT00216255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagoclone
Study NCT00216255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03470922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified day
Study NCT03470922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT01231217 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Green tea (Camellia sinensis)
Description: Patients are recommended to drink at least 5 cups of green tea per day
Study NCT01231217 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coffee
Description: Patients are recommended to drink as much coffee as they tolerate.
Study NCT00197678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins-Multiples of RDA
Description: 20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
Study NCT00197678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins-Single RDA
Description: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
Study NCT03093181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Washout / Standard Cleanser
Description: Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
Study NCT03093181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout / Standard Cleanser
Description: Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
Study NCT03093181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
Study NCT03211767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged garlic extract
Description: Each capsule contains 600mg of aged garlic extract powder
Study NCT03211767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each capsule contains cellulose as a filler.
Study NCT03093181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control cleanser
Description: Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
Study NCT03093181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control moisturiser
Description: Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
Study NCT04499703 — intervention group
Intervention type: DEVICE
Intervention: RHMS-RTM
Description: Assessment of retinal thickness
Study NCT02608957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latella Knee Implant System
Study NCT04499703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: Assessment of retinal structure
Study NCT04616443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus
Study NCT04616443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HX008 injection
Description: Recombinant humanized anti-PD-1 monoclonal antibody of injection
Study NCT03903172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Description: Abdominal binder
Study NCT00746005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
Study NCT00746005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo, sunflower oil
Description: 3 g of sunflower oil
Study NCT02821533 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE
Description: TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
Study NCT02821533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
Study NCT03933488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.
Study NCT03933488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Placebo
Description: TAK-994 placebo-matching tablets.
Study NCT04525521 — intervention group
Intervention type: OTHER
Intervention: Hand sanitizer and hand washing
Description: All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
Study NCT04149080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIM + polypropylene membrane
Description: After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
Study NCT04149080 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
Study NCT00622765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule twice daily
Study NCT00622765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 5 mg capsule twice daily
Study NCT00622765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 10 mg capsule twice daily
Study NCT00622765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 15 mg capsule twice daily
Study NCT04552197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64251330
Description: JNJ-64251330 tablet will be administered orally.
Study NCT04552197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib tablets will be administered orally.
Study NCT01279746 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound compression of femoral and popliteal veins
Description: Bedside ultrasound compression of femoral and popliteal veins.
Study NCT00774917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Numen
Description: Numen Co-Cr coronary stent implant
Study NCT03876925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
Study NCT00405301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
Description: Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.